ArticleRegenerative biomaterials2026
Synergistic self-assembly and crosslinking yield a durable, bioactive, and injectable recombinant collagen implant for photoaging therapy.
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sustained ultraviolet (UV) irradiation upregulates matrix metalloproteinases (MMPs) activity, exacerbates collagen degradation, and triggers inflammatory signaling, leading to extracellular matrix (ECM) disorganization and skin photoaging. While animal-derived collagens are widely used in clinical applications, their immunogenicity and batch variability limit safety and consistency. Recombinant collagen provides a safer and more controllable alternative. However, poor fibrillogenesis, limited structural stability, and rapid enzymatic degradation hinder long-term performance. Here, we developed an injectable recombinant collagen nanofiber implant (B-SARCI) through the synergistic integration of molecular self-assembly and mild 1,4-butanediol diglycidyl ether (BDDE) crosslinking. This dual strategy preserves excellent injectability while simultaneously enhancing thermal stability, and enzymatic resistance. B-SARCI improved fibroblast attachment and proliferation, promoted migration, and facilitated differentiation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.